EPHA2 and cancer: Using an EphA2 internalization assay in cancer cell lines we recognized that, similar to the ephrin ligands, dimeric versions of these synthetic agents possessed greatly increased cellular efficacy in causing receptor degradation, compared to their monomeric versions.